



OA RENEWS CONTRACT WITH AVENTIS FOR TAXOTERE®

Effective January 1, 2003 Oncology Associates has renewed its contract with Aventis for Taxotere® (docetaxel) for injection concentrate.

Taxotere® (docetaxel) is an antineoplastic agent belonging to the taxoid family. It is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy and as first-line therapy in patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with cisplatin, who have not received prior chemotherapy and/or the treatment of

patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy.

“Aventis has one of the industry’s leading oncology portfolios, which includes Taxotere, one of the most widely used chemotherapeutic agents worldwide. We are pleased to continue offering Taxotere® to our membership,” states Joe Lewarski, Chief Operating Officer and Managing Partner for Oncology Associates.

If your practice has not already joined the Aventis contract for Taxotere®, contact Oncology Associates at 888-732-7352.

NDC #	PRODUCT NAME	VIAL SIZE
00075-8001-20	Taxotere®	20 mg
00075-8001-80	Taxotere®	80 mg



OA RENEWS CONTRACT WITH WYETH/GENETICS INSTITUTE FOR NEUMEGA®

Effective January 1, 2003 Oncology Associates has renewed its contract with Wyeth/Genetics Institute for Neumega®.

Neumega® is indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia. Efficacy was demonstrated in patients who had experienced severe thrombocytopenia following the previous chemotherapy cycle. Neumega® is not indicated following myeloablative chemotherapy.

“We are extremely pleased we have

renewed our contract with Wyeth Genetics Institute for Neumega,” states Dennis Wollschleger, CEO of Oncology Associates. “Wyeth/Genetics Institute’s reputation as a leader in the discovery, development and manufacturing of chemotherapy agents is only one of the many reasons we have continued this valuable partnership.”

Wyeth/Genetics is one of the world’s largest research-driven pharmaceutical and health care products companies. If your practice has not already joined the Wyeth/Genetics contract for Neumega®, contact Oncology Associates at 888-732-7352.

NDC #	PRODUCT NAME	VIAL SIZE	VIALS PER BOX
58394-004-01	Neumega®	5 mg	1 vial 1x10
58394-004-02	Neumega®	5 mg	1x7

OA’S CURRENT CONTRACTS:

AMGEN
800.447.1000

ASPEN CONSULTING GROUP LTD.
877.238.7032

AVENTIS
800.996.6626
(Reimbursement Hotline)

BEDFORD LABS
800.562.4797

GLAXOSMITHKLINE
888.825.5249

MEDICAL SPECIALITIES
800.967.6400

MEDIMMUNE ONCOLOGY, INC.
877.633.4411

MDINTOUCH
866.774.0002

MGI PHARMA
952.346.4700

NOVIDEA HEALTHCARE
877.503.1455

ORTHO BIOTECH
800.325.7504

PHARMION
720.564.9100

ROCHE, INC.
973.235.5000

WYETH/GENETICS INSTITUTE
617.876.1170